- Home
- JKHY vs EXAS Comparison
JKHY vs EXAS Comparison
Compare JKHY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKHY
- EXAS
- Stock Information
- Founded
- JKHY 1976
- EXAS 1995
- Country
- JKHY United States
- EXAS United States
- Employees
- JKHY N/A
- EXAS N/A
- Industry
- JKHY Retail: Computer Software & Peripheral Equipment
- EXAS Medical Specialities
- Sector
- JKHY Technology
- EXAS Health Care
- Exchange
- JKHY Nasdaq
- EXAS Nasdaq
- Market Cap
- JKHY 12.1B
- EXAS 10.7B
- IPO Year
- JKHY N/A
- EXAS N/A
- Fundamental
- Price
- JKHY $181.32
- EXAS $53.36
- Analyst Decision
- JKHY Hold
- EXAS Strong Buy
- Analyst Count
- JKHY 8
- EXAS 20
- Target Price
- JKHY $185.38
- EXAS $70.16
- AVG Volume (30 Days)
- JKHY 501.1K
- EXAS 2.8M
- Earning Date
- JKHY 08-19-2025
- EXAS 07-30-2025
- Dividend Yield
- JKHY 1.28%
- EXAS N/A
- EPS Growth
- JKHY 13.10
- EXAS N/A
- EPS
- JKHY 5.87
- EXAS N/A
- Revenue
- JKHY $2,319,828,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- JKHY $8.37
- EXAS $14.58
- Revenue Next Year
- JKHY $6.79
- EXAS $12.75
- P/E Ratio
- JKHY $30.89
- EXAS N/A
- Revenue Growth
- JKHY 5.92
- EXAS 11.57
- 52 Week Low
- JKHY $158.62
- EXAS $39.97
- 52 Week High
- JKHY $196.00
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- JKHY 53.54
- EXAS 49.61
- Support Level
- JKHY $177.37
- EXAS $52.60
- Resistance Level
- JKHY $183.31
- EXAS $55.09
- Average True Range (ATR)
- JKHY 3.19
- EXAS 2.09
- MACD
- JKHY 0.02
- EXAS -0.01
- Stochastic Oscillator
- JKHY 65.81
- EXAS 44.73
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for us banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.